Clinical Trials Day 2023
JOIN US ON: Tuesday, December 5, 2023 START: 11:00 AM
Biopharma R&D is once again zeroing in on the greatest efficiency in developing drugs for mass markets — but the threat of a rocky world stage combined with VC disruption efforts are creating the latest set of hurdles facing the industry. How can you get a clean, convincing set of data to regulators while facing the current climate? And without blowing the budget with unnecessary or redundant efforts? Our experts will unpack the lessons to be learned and how they affect today’s trial pipeline — join us as we map the future of drug development.
Geopolitical tensions are escalating worldwide, posing new hurdles for drug research spanning multiple countries. Last year's trial disruptions in Ukraine underscored how quickly years of work can unravel. How can the industry navigate the latest crises playing out on the world stage? Find out what strategies drugmakers and CROs are using to advance their research amidst the instability.(30-40 mins)
Venture Partner, ARCH Venture Partners
Senior Fellow for Global Health, Council on Foreign Relations
President & CEO
South African Medical Research Council
The Asia Group
The White House has made a push to expand US clinical trials infrastructure, and executive editor Drew Armstrong speaks with Grail Sipes from the Office of Science and Technology Policy about the effort.
WH Office of Science and Technology Policy
Venture capitalists have started pouring more money into the contract research side of biopharma, funneling more investments into startups aiming to disrupt the space with an eye on competing against the big players. Do these changemakers have what it takes to challenge the CRO giants? Our panelists will weigh in on how incumbents are responding and what's at stake for the drug companies that work with them.
Chief Clinical Trials Officer
SVP, Development Operations, Portfolio Management & Biostatistics Data Management